Gamma delta (γδ) T cells hold significant potential for unmet medical needs. Yet they are more challenging to source than ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

Recent research from University College London demonstrated how engineered immune cells called gamma-delta T-cells could act as delivery vehicles for anti-cancer antibodies. In this approach ...

NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an upcoming ...

ACE1831 is an allogeneic gamma delta T cell therapy candidate targeting CD20-expressing cells currently being investigated in non-Hodgkin's lymphoma (NHL) The planned clinical study will be executed ...

In a recent study published at Cell Reports Medicine the team identified three key success markers: the CD4:CD8 ratio, exhaustion signals and the expansion of gamma-delta cytotoxic T-cells.

Reported 100% of Acute Myeloid Leukemia (AML) patients treated in INB-100 remain in complete remission (CR) at the 2024 European Hematology ...

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for ...

Plenary Oral Presentation at SNO will provide latest clinical trial results from the previously enrolled INB-200 studies of autologous gamma-delta T cells for newly diagnosed glioblastoma (GBM) ...

Jonathan Fisher works for University College London and is an inventor on patents pertaining to gamma-delta T cell immunotherapy. In the past 5 years he has received research funding from UKRI ...

IND clearance paves the way for Acepodia to enter the clinic for the first time with its autoimmune program ACE1831 is an allogeneic gamma delta T cell therapy ...